Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Study protocol for a randomised controlled trial: Treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP)

  • Mazarico, E.
  • Peguero, A.
  • Camprubí, M.
  • Rovira, C.
  • Gomez Roig, M.D.
  • Oros, D.
  • Ibáñez-Burillo, P.
  • Schoorlemmer, J.
  • Masoller, N.
  • Tàssies, M.D.
  • Figueras, F.
Introduction The incidence of intrauterine growth restriction (IUGR) is estimated at about 3% of pregnancies, and it is associated with 30% of all perinatal mortality and severe morbidity with adverse neurodevelopmental and cardiovascular health consequences in adult life. Early onset IUGR represents 20%-30% of all cases and is highly associated with severe placental insufficiency. The existing evidence suggests that low molecular weight heparin (LMWH) has effects beyond its antithrombotic action, improving placental microvessel structure and function of pregnant women with vascular obstetric complications by normalising proangiogenic and antiapoptotic protein levels, cytokines and inflammatory factors. The objective of our study is to demonstrate the effectiveness of LMWH in prolonging gestation in pregnancies with early-onset IUGR. Methods and analysis This is a multicentre, triple-blind, parallel-arm randomised clinical trial. Singleton pregnancies qualifying for early (20-32 weeks at diagnosis) placental IUGR (according to Delphi criteria) will be randomised to subcutaneous treatment with bemiparin 3500 IU/0.2 mL/day or placebo from inclusion at diagnosis to the time of delivery. Analyses will be based on originally assigned groups (intention-to-treat). The primary objective will be analysed by comparing gestational age and prolongation of pregnancy (days) in each group with Student''s t-tests for independent samples and by comparing Kaplan-Maier survival curves (from inclusion to delivery, log-rank test). A linear regression model for gestational age at birth will consider the following covariates: Gestational age at inclusion (continuous) and pre-eclampsia (binary). Ethics and dissemination The study will be conducted in accordance with the principles of Good Clinical Practice. This study was approved by the Clinical Research Ethics Committee (CEIC) of Sant Joan de Déu Hospital, on 13 July 2017. The trial is registered in the public registry www.clinicaltrial.gov. according to Science Law 14/2011, and the results will be published in an open access journal.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation

  • Gambato, Martina
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Koutsoudakis, George
  • González, Patricia
  • Caro-Pérez, Noelia
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • García-González, Neris
  • González-Candelas, Fernando|||0000-0002-0879-5798
  • Ignacio Esteban, Juan
  • Crespo, Gonzalo|||0000-0002-1178-4897
  • Navasa, Miquel|||0000-0002-3130-9604
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Cholestatic hepatitis C (CHC) is a severe form of hepatitis C virus (HCV) infection recurrence that leads to high graft loss rates early after liver transplantation (LT). To investigate the pathogenic mechanisms of CHC, we analysed HCV quasispecies in CHC patients compared to a control group (mild hepatitis C recurrence) by deep pyrosequencing. At the time of LT, NS5B quasispecies complexity was similar between the two groups but, after LT, it decreased more sharply in CHC patients than in the control group. Interestingly, the major variant before LT propagated efficiently and remained as the dominant sequence after LT in 62% of CHC patients versus 11% of controls (P=0.031). Sequence analysis of the complete nonstructural region in a limited number of patients revealed a potential 12 aa signature specific to the CHC group. These data suggest that intrinsic molecular determinants in the circulating HCV quasispecies may provide a fitness advantage, contributing to the development of CHC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals

  • Egmond, Elfi|||0000-0003-1897-0067
  • Mariño, Zoe|||0000-0001-6321-9534
  • Navinés, Ricard|||0000-0002-6999-7510
  • Oriolo, Giovanni
  • Pla, Anna
  • Bartres, Concepció
  • Lens, Sabela|||0000-0003-4900-411X
  • Forns, Xavier|||0000-0002-8188-1764
  • Martin-Santos, Rocio|||0000-0003-4150-4726
Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i.e., interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depression in a real-life prospective cohort of chronic hepatitis C patients treated with the new DAAs. The sample was recruited from a cohort of 91 patients with hepatitis C, of both sexes, with advanced level of fibrosis and no HIV coinfection, consecutively enrolled during a 6-month period for DAA treatment; those euthymic at baseline (n=54) were selected. All were evaluated through the depression module of the Patient Health Questionnaire (PHQ-9-DSM-IV), at three time points: baseline, 4 weeks, and end-of-treatment. The cumulative incidence (95%CI) of major depression and any depressive disorder during DAA treatment was 13% (6.4-24.4) and 46.3% (33.7-59.4), respectively. No differences were observed between those patients with and without cirrhosis or ribavirin treatment (p.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

  • García López, Mireia|||0000-0002-9643-7172
  • Lens, Sabela|||0000-0003-4900-411X
  • Pallett, Laura J.
  • Testoni, Barbara
  • Rodríguez-Tajes, Sergio|||0000-0002-3189-7557
  • Mariño, Zoe|||0000-0001-6321-9534
  • Bartres, Concepció
  • García-Pras, Ester
  • Leonel, Thais
  • Perpiñán, Elena
  • Lozano, Juan José
  • Rodríguez Frías, Francisco|||0000-0002-9128-7013
  • Koutsoudakis, George
  • Zoulim, Fabien
  • Maini, Mala K.
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Factors associated with a successful outcome upon nucleos(t)ide analogue (NA) treatment withdrawal in HBeAg-negative chronic hepatitis B (CHB) patients have yet to be clarified. The objective of this study was to analyse the HBV-specific T cell response, in parallel with peripheral and intrahepatic viral parameters, in patients undergoing NA discontinuation. Twenty-seven patients without cirrhosis with HBeAg-negative CHB with complete viral suppression (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Erratum, Neutrophil and monocyte function in patients with chronic hepatitis C undergoing antiviral therapy with regimens containing protease inhibitors with and without interferon (PLoS ONE (2016) 11:11 (e0166631) DOI: 10.1371/journal.pone.0166631)

  • Gambato, Martina
  • Caro-Pérez, Noelia
  • González, Patricia
  • Cañete Hidalgo, Nuria|||0000-0001-9501-7590
  • Mariño, Zoe|||0000-0001-6321-9534
  • Lens, Sabela|||0000-0003-4900-411X
  • Bonacci, Martín
  • Bartres, Concepció
  • Sánchez Tapias, José María
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Forns, Xavier|||0000-0002-8188-1764
  • Juan, Manel|||0000-0002-3064-1648
  • Pérez-Del-Pulgar, Sofía
  • Londoño, Maria Carlota|||0000-0002-6533-1586
There are errors in the Funding section. The correct funding information is as follows: SPP has received a grant from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (PI13/00155), co-funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, Una manera de hacer Europa. XF has received a grant from L' Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2014-SGR-605). XF was also supported in part by grant PI15/00151, integrated in Plan Nacional de I+D+I and funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER-"Una manera de Hacer Europa"). MG was funded with an EASL Entry Level Research Fellowship (Dame Sheila Sherlock EASL Fellowship Programme).